Less is more? Antidepressant effects of short-acting psychedelics DOI
Johannes G. Ramaekers

Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

Language: Английский

Psychedelics in Psychiatry: Oh, What A Trip! DOI
Gregory A. Fonzo, Charles B. Nemeroff, Ned H. Kalin

et al.

American Journal of Psychiatry, Journal Year: 2025, Volume and Issue: 182(1), P. 1 - 5

Published: Jan. 1, 2025

Language: Английский

Citations

1
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression DOI
Marcelo Falchi, Fernanda Palhano-Fontes, Isabel Wießner

et al.

Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

Language: Английский

Citations

1
Pharmacological Monotherapy for Depressive Disorders: Current and Future, a Narrative Review DOI Creative Commons
Keming Gao, Evrim Bayrak Oruc, Buket Koparal

et al.

Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 558 - 558

Published: March 21, 2025

Objective: To narratively review currently available antidepressants and future potential as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), norepinephrine (SNRIs), dopamine inhibitor (bupropion), tricyclic (TCAs), monoamine oxidase (MAOIs) were reviewed according to results from Sequenced Treatment Alternatives Relieve Depression (STAR*D) Study systematic reviews. For rest antidepressants, a PubMed/Medline search was conducted with priority drugs in development disorders, PubMed, Google, Clinicaltrials.gov databases used. Results: The STAR*D demonstrated that sertraline, venlafaxine, bupropion had similar efficacy patients major disorder (MDD) who failed citalopram. A network meta-analyses randomized, placebo-controlled trials found SSRIs, SNRIs, bupropion, TCAs, mirtazapine, agomelatine relative compared placebo, but different acceptability. Gepirone more failed/negative studies smaller effect size placebo other antidepressants. combination dextromethorphan ketamine infusion, intranasal esketamine faster onset action monoamine-based monotherapy. Brexanolone zuranolone are effective postpartum depression (PPD), MDD or adjunctive therapy very small. Psychedelics, glutamate receptor-related agents, kappa opioid receptor antagonists, orexin new anti-inflammatory biomarker-based antidepressant have been under investigation Psychedelics showed action, large size, long durability. Conclusions: Monoamine-based likely continue be mainstream disorder. NMDA antagonists neurosteroid will play bigger role improvement accessibility. may become game changer if phase III validate their safety

Language: Английский

Citations

0
Less is more? Antidepressant effects of short-acting psychedelics DOI
Johannes G. Ramaekers

Neuropsychopharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

Language: Английский

Citations

0